- Home
- PBYI vs SGHT Comparison
PBYI vs SGHT Comparison
Compare PBYI & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- SGHT
- Stock Information
- Founded
- PBYI 2010
- SGHT 2011
- Country
- PBYI United States
- SGHT United States
- Employees
- PBYI N/A
- SGHT N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- SGHT Medical Specialities
- Sector
- PBYI Health Care
- SGHT Health Care
- Exchange
- PBYI Nasdaq
- SGHT Nasdaq
- Market Cap
- PBYI 138.4M
- SGHT 140.1M
- IPO Year
- PBYI N/A
- SGHT 2021
- Fundamental
- Price
- PBYI $2.86
- SGHT $2.66
- Analyst Decision
- PBYI Strong Buy
- SGHT Buy
- Analyst Count
- PBYI 1
- SGHT 7
- Target Price
- PBYI $7.00
- SGHT $3.83
- AVG Volume (30 Days)
- PBYI 334.3K
- SGHT 182.6K
- Earning Date
- PBYI 05-01-2025
- SGHT 05-01-2025
- Dividend Yield
- PBYI N/A
- SGHT N/A
- EPS Growth
- PBYI 37.78
- SGHT N/A
- EPS
- PBYI 0.62
- SGHT N/A
- Revenue
- PBYI $230,468,000.00
- SGHT $79,866,000.00
- Revenue This Year
- PBYI N/A
- SGHT N/A
- Revenue Next Year
- PBYI N/A
- SGHT $11.17
- P/E Ratio
- PBYI $4.61
- SGHT N/A
- Revenue Growth
- PBYI N/A
- SGHT N/A
- 52 Week Low
- PBYI $2.23
- SGHT $2.03
- 52 Week High
- PBYI $5.34
- SGHT $8.45
- Technical
- Relative Strength Index (RSI)
- PBYI 42.27
- SGHT 55.32
- Support Level
- PBYI $2.83
- SGHT $2.03
- Resistance Level
- PBYI $2.99
- SGHT $2.59
- Average True Range (ATR)
- PBYI 0.17
- SGHT 0.27
- MACD
- PBYI -0.01
- SGHT 0.04
- Stochastic Oscillator
- PBYI 50.00
- SGHT 91.30
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.